Merz Therapeutics Strengthens European Footprint with Launch of New Affiliate in Poland
Merz Therapeutics GmbH, a globally recognized leader in neurology-focused specialty pharmaceuticals, has officially announced the opening of its new affiliate in Warsaw, Poland. This strategic expansion marks a significant step in the company’s ongoing efforts to strengthen its presence across Central and Eastern Europe, while demonstrating its long-term commitment to patients, healthcare professionals, and strategic partners in Poland.
With this move, Merz Therapeutics will now assume full responsibility for its operations in the country, enabling a more direct and responsive approach to meeting local healthcare needs. Poland has emerged as a key market within the region due to its growing healthcare sector, evolving patient needs, and increasing demand for innovative therapeutic solutions. By establishing a dedicated local presence, Merz aims to enhance collaboration with medical professionals, optimize operational efficiency, and tailor its programs to the specific requirements of the Polish healthcare landscape.
A Milestone in Strategic Growth
“Establishing our own affiliate in Poland marks another important milestone in our growth journey,” said Andrea von der Lippe, President of the International Markets region at Merz Therapeutics. “A direct presence allows us to work even more closely with the Polish medical community, ensuring continuity for patients while creating the foundation for sustainable growth. We look forward to strengthening our relationships with healthcare providers and delivering innovative therapies that meet the unique needs of this market.”
Merz Therapeutics’ expansion in Poland reflects the company’s broader strategy of investing in high-potential markets to ensure long-term business sustainability and improve patient access to specialty therapies. The move comes on the heels of several years of successful collaboration with local partners, during which Merz gained a deep understanding of the Polish healthcare system, regulatory environment, and patient landscape.
Building on Existing Partnerships
Prior to the establishment of its Warsaw affiliate, Merz Therapeutics had maintained a presence in Poland through its former partner, Egora. Egora played a pivotal role in laying the groundwork for Merz’s business in the country, facilitating the introduction of the company’s portfolio and supporting the development of relationships with healthcare professionals. The contributions of Egora are formally acknowledged by Merz Therapeutics as a key factor in the company’s readiness to establish a fully owned local affiliate.
Product distribution in Poland will continue through Cefarm, one of the country’s leading pharmaceutical distributors. This ensures that access to Merz’s range of therapies remains uninterrupted, while the company gradually transitions to a model that allows for greater control over operations, customer engagement, and market responsiveness.
Leadership Appointment
To spearhead the new affiliate, Merz Therapeutics has appointed Jolanta Dilling-Sulimierska as General Manager of Merz Therapeutics Poland. In her new role, Dilling-Sulimierska will be responsible for overseeing day-to-day operations, driving business development, and fostering strategic partnerships with healthcare stakeholders, including hospitals, medical associations, and regulatory authorities.
“I am honored to take on this role and excited to lead Merz Therapeutics’ new chapter in Poland,” said Dilling-Sulimierska. “Our primary focus will be on supporting patients and healthcare professionals through collaboration, education, and the responsible growth of our therapies. Together with our partners, we aim to make a tangible difference in patient care.”
Dilling-Sulimierska brings extensive experience in pharmaceutical management and business development, having previously held senior leadership positions in the Polish healthcare sector. Her appointment underscores Merz’s commitment to local expertise and market-specific leadership, which are essential for driving growth and ensuring high-quality patient outcomes.
Commitment to Patients and Healthcare Professionals
Merz Therapeutics has consistently prioritized patient-centered care and innovative medical solutions. By establishing a direct presence in Poland, the company aims to further strengthen this commitment by engaging more closely with local healthcare professionals, providing targeted educational initiatives, and supporting clinical and community programs that improve patient outcomes.
Through its Warsaw affiliate, Merz plans to enhance access to its portfolio of neurology-focused therapies, which includes treatments for movement disorders, cognitive impairments, and other sphttps://thepharmadata.com/merz-therapeutics-enrolls-first-patients-in/ecialty indications. By aligning operations more closely with local needs, the company can respond more rapidly to changes in patient demand, healthcare regulations, and treatment practices, ultimately delivering greater value to both patients and providers.
Strategic Importance of Poland
Poland represents a strategic market for Merz Therapeutics within Central and Eastern Europe. The country’s healthcare system has been undergoing significant modernization, with increasing investment in specialty care, infrastructure, and advanced therapeutic solutions. At the same time, Poland’s growing population and rising prevalence of neurological and other chronic diseases underscore the need for innovative treatment options.
Merz’s establishment of a dedicated affiliate allows the company to play a more proactive role in addressing these needs. Through direct engagement with physicians, hospitals, and patient organizations, the company can better understand local treatment pathways, provide tailored support, and contribute to initiatives that improve overall healthcare quality in Poland.
Future Outlook
The creation of Merz Therapeutics Poland marks the beginning of a new phase in the company’s expansion strategy. Looking ahead, the Warsaw affiliate will focus on deepening collaborations with the medical community, enhancing access to Merz’s therapies, and exploring opportunities for clinical research and innovation in the region.
“We view this expansion as a long-term investment in the Polish healthcare landscape,” said Andrea von der Lippe. “Our presence here allows us to contribute more directly to the advancement of patient care, collaborate on medical education, and ultimately strengthen the healthcare system by making innovative therapies more accessible.”
Merz Therapeutics’ launch of its Warsaw affiliate represents a significant milestone in the company’s international growth journey. By taking direct responsibility for operations in Poland, appointing experienced local leadership, and continuing strong partnerships with distributors and healthcare providers, Merz is poised to make a meaningful impact on the lives of patients in the country.
This expansion not only reinforces Merz Therapeutics’ commitment to Central and Eastern Europe but also exemplifies the company’s broader mission to deliver specialty pharmaceutical solutions that improve patient outcomes globally. Through sustained investment, collaboration, and innovation, Merz Therapeutics Poland is expected to become a cornerstone of the company’s regional strategy, driving both growth and positive change in healthcare.
